Article

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

Johannes Gutenberg-Universität Mainz, Mayence, Rheinland-Pfalz, Germany
Journal of Pediatrics (Impact Factor: 3.74). 12/2006; 149(5):603-610. DOI: 10.1016/j.jpeds.2006.06.016
Source: PubMed

ABSTRACT The safety of a booster dose of a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis-containing vaccine.
Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria-tetanus-acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis-containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular pertussis-containing vaccine dose) versus rates in these same individuals after vaccination with their fifth DTaP dose were assessed.
After Tdap, pain (63.6%), redness (51.7%), and swelling (41.4%) were the most frequently reported AEs. Large injection site swelling (swelling > 100 mm, arm circumference increase > 50 mm or diffuse swelling interfering with daily activities) occurred in three adolescents and resolved without sequelae. After the sixth dose of acellular pertussis-containing vaccine, adolescents reported more pain and less redness and swelling compared with incidences of these AEs reported when these same individuals received their fifth DTaP dose.
These results suggest that Tdap is well tolerated as a sixth consecutive dose of acellular pertussis-containing vaccine.

0 Followers
 · 
143 Views
  • BioDrugs 01/2006; 20(6). DOI:10.2165/00063030-200620060-00008 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The results of influence of ionizing radiation (gamma-quanta with doses 10<sup>2</sup>-10<sup>9</sup> Gy, high energy electrons and fast neutrons with fluences 10<sup>12</sup>-10<sup>19</sup> cm<sup>-2</sup>) on optical properties and laser performance of YAlO<sub>3</sub>:Nd and Gd<sub>3</sub>Ga<sub>3</sub>O<sub>12</sub>:Nd crystals for solid state lasers of space based LIDAR systems are presented. The mechanisms of radiation defects formation and the origin of color centers are discussed.
    Modern Problems of Radio Engineering, Telecommunications and Computer Science, 2002. Proceedings of the International Conference; 02/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis vaccine (dTpa; Boostrix) contains reduced quantities of the same toxoids/antigens found in a diphtheria, tetanus, and acellular pertussis vaccine (DTPa; Infanrix) used for the primary immunization series in children. A single dose of dTpa (Boostrix) is indicated for booster vaccination against diphtheria, tetanus, and pertussis in individuals aged >or=4 years in Europe and Canada, in individuals aged >or=10 years in Australia, and in adolescents aged 10-18 years in the US.A single booster dose of dTpa (Boostrix) was safe and highly immunogenic for all its component toxoids/antigens when administered to adults, adolescents (including those previously unvaccinated), and children aged >or=4 years in clinical trials conducted in various countries worldwide. It was also well tolerated, as was a second (repeat) dose administered to a small number of adolescents who had previously received the vaccine as a preschool booster. Vaccinees generally reported a low incidence of severe/grade 3, solicited, local and general adverse events during the 1-month postvaccination period.Current recommendations for dTpa usage vary from country to country; they include one dose only in adolescence or adulthood (e.g. Australia, Canada, France, Switzerland, and the US), one dose at preschool age and one in adolescence (Germany), and one dose in adolescence followed by regular (10-year) doses during adulthood (Austria). Available data support the use of dTpa (Boostrix) in place of the combined diphtheria, tetanus, whole-cell pertussis vaccine (DTwP) or DTPa booster dose in preschool children and/or the reduced-antigen, combined diphtheria, tetanus vaccine (Td) booster dose in adolescents, as well as in place of a regular Td booster dose in adults who have not previously received the vaccine.
    BioDrugs 01/2006; 20(6):371-89. · 2.12 Impact Factor